Table 3 Response to ICIs therapy based on the RF model
From: A novel model for predicting immunotherapy response and prognosis in NSCLC patients
Survival prediction | Low Risk | High Risk | X2 | p |
|---|---|---|---|---|
For training cohort (n=) | n = 92 | n = 122 |  |  |
  Best overall response-no. (%) |  |  | 19.31 | <0.001 |
  Complete Response (CR) | 6 (6.5) | 1 (0.8) |  |  |
  Partial response (PR) | 34 (37.0) | 32 (26.2) |  |  |
  Stable disease (SD) | 35 (38.0) | 35 (28.7) |  |  |
  Progressive disease (PD) | 17 (18.5) | 54 (44.3) |  |  |
For validation cohort (n=) | n = 37 | n = 68 |  |  |
  Best overall response-no. (%) |  |  | 11.212 | 0.006 |
  Complete Response (CR) | 1 (2.7) | 1 (1.5) |  |  |
  Partial response (PR) | 17 (45.9) | 25 (36.8) |  |  |
  Stable disease (SD) | 15 (40.5) | 15 (22.1) |  |  |
  Progressive disease (PD) | 4 (10.8) | 27 (39.7) |  |  |